United Therapeutics Corp [UTHR] stock is trading at $325.48, up 2.08%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The UTHR shares have gain 5.80% over the last week, with a monthly amount glided 10.76%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
United Therapeutics Corp [NASDAQ: UTHR] stock has seen the most recent analyst activity on June 02, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $405. Previously, Wells Fargo downgraded its rating to Equal Weight on April 25, 2025. On April 21, 2025, upgrade upgraded it’s rating to Neutral but maintained its price target of $314 on the stock. Morgan Stanley downgraded its rating to a Equal-Weight and increased its price target to $321 on July 11, 2024. Goldman upgraded its rating to a Neutral and raised its price target to $215 on February 12, 2024. Leerink Partners started tracking with a Outperform rating for this stock on February 05, 2024, and assigned it a price target of $330. In a note dated December 08, 2023, Wells Fargo initiated an Overweight rating and provided a target price of $309 on this stock.
United Therapeutics Corp [UTHR] stock has fluctuated between $266.98 and $417.82 over the past year. Currently, Wall Street analysts expect the stock to reach $314 within the next 12 months. United Therapeutics Corp [NASDAQ: UTHR] shares were valued at $325.48 at the most recent close of the market. An investor can expect a potential drop of -3.53% based on the average UTHR price forecast.
Analyzing the UTHR fundamentals
United Therapeutics Corp [NASDAQ:UTHR] reported sales of 2.99B for the trailing twelve months, which represents a growth of 17.22%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at 0.47%, Pretax Profit Margin comes in at 0.52%, and Net Profit Margin reading is 0.4%. To continue investigating profitability, this company’s Return on Assets is posted at 0.16, Equity is 0.19 and Total Capital is 0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 318.36 points at the first support level, and at 311.24 for the second support level. However, for the 1st resistance point, the stock is sitting at 329.80, and for the 2nd resistance point, it is at 334.12.
Ratios To Look Out For
For context, United Therapeutics Corp’s Current Ratio is 5.46. Also, the Quick Ratio is 5.23, while the Cash Ratio stands at 2.63. Considering the valuation of this stock, the price to sales ratio is 4.90, the price to book ratio is 2.16 and price to earnings (TTM) ratio is 12.99.
Transactions by insiders
Recent insider trading involved JAMES EDGEMOND, Officer, that happened on Jun 02 ’25 when 0.11 million shares were purchased. EVP & GENERAL COUNSEL, MAHON PAUL A completed a deal on May 29 ’25 to sell 11000.0 shares. Meanwhile, Officer PAUL MAHON bought 11000.0 shares on May 29 ’25.
